Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is well-positioned in the generic drug market, with a strong presence in North America, Europe, Japan, Russia, and Israeli markets. Their innovative medicine portfolio and biosimilars in neurology and immunology add to their growth potential. With unique dosing profiles and a differentiated "double-whammy" mechanism targeting both IL-2 and IL-15, Teva may outperform competitors in the autoimmune treatment space and capture a $2.5 billion franchise. Upcoming catalysts in 2026, including topline data for vitiligo and celiac disease, could drive significant value for the company. Furthermore, Teva's track record of executing well on its Pivot to Growth plan and potential line of sight to 30% operating margin by 2027 make the stock a Buy rating.

Bears say

Teva Pharmaceutical Indus is facing a challenging market environment as the generic drug industry becomes increasingly fragmented and dominated by antipsychotics causing severe side effects. Despite the recent acquisition, Teva's portfolio and pipeline remain stagnant, and its success relies heavily on execution. Weak sales performance in the 1Q and lack of significant growth drivers beyond 2027 indicate a downward outlook for the stock.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.